Medical cannabis collection · Sources reviewed 11 October 2026
Palliative care means attending to suffering, comfort and quality of life. For someone with multiple sclerosis, symptom management can sit alongside rehabilitation and treatment directed at the disease. It should not be read as a declaration that nothing else can be done.
On this page
Start with the person’s daily difficulties
MS affects people in different ways. Stiffness, spasms, pain, fatigue, bowel or bladder symptoms and cognitive or emotional difficulties may require different assessments. A single treatment is unlikely to address the entire pattern. A plan should be built with the person and the relevant professionals, with goals that can be understood in daily life.
For one person that may mean easier transfers; for another, fewer painful spasms at night or enough energy to join a family activity. The usefulness of treatment depends on those outcomes as well as on symptom scales. NICE guidance on MS management.
Where a cannabis-based medicine fits
Sativex, or nabiximols, is a standardised THC:CBD mouth spray used in selected adults with MS-related spasticity. Its role is symptom management. It is not a disease-modifying treatment and should not be described as repairing myelin, preventing relapses or curing MS. Sativex product information.
NICE recommends an initial trial under defined conditions when other pharmacological treatments have been ineffective, with continued treatment dependent on a sufficient early response. The detailed MS spasticity and Sativex article explains the four-week assessment and how to interpret the patient-reported threshold.
Less muscle tone is not always better function
Some people use increased tone to support standing or transfers. Reducing it too far can make those tasks harder. Likewise, fewer spasms may be offset by dizziness, weakness or reduced alertness. Treatment needs to be reviewed against what the person wants to do, not just whether a limb feels less stiff.
Infections, constipation, pain and positioning can aggravate spasticity and may need attention in their own right. Physiotherapy, equipment, rehabilitation and established medicines remain part of the wider plan. Cannabinoid treatment, where appropriate, belongs within that plan.
What about shop-bought CBD?
CBD is pharmacologically active even though it does not produce the characteristic THC high. A consumer CBD product is not equivalent to the defined THC:CBD spray used in the spasticity evidence. A low THC content does not make a product inactive, nor does the word CBD establish effectiveness for MS symptoms.
The relevant question is what was tested, for which symptom, and with what benefit and harm. Product comparisons and prescription changes should be discussed with the clinical team.
Bee sting or bee venom “therapy”
No. Just no.
A randomised crossover study in 26 people with relapsing forms of MS found no improvement in disease activity, disability, fatigue or quality of life with the tested bee-sting treatment. The unusual nature of an intervention is not evidence that it works. Wesselius and colleagues, 2005.
A useful review includes comfort and capability
Ask what has become easier, what remains difficult and what the treatment has made worse. Include the person’s priorities and, with permission, observations from family or carers. A change in symptoms or new neurological difficulty still deserves assessment; it should not be explained away as a psychological failure or as a reason to keep escalating an unhelpful treatment.
The purpose of care is to reduce suffering and preserve meaningful activity wherever possible. Cannabis-based medicine has a limited, specific place within that work. Its value is best assessed honestly, alongside the rest of the person’s care.
References and further reading
Educational information, not an individual prescribing plan. Decisions about medicines belong with the treating clinician. External reference links open in a new tab.